TH
BMRN icon

Timber Hill’s BioMarin Pharmaceuticals BMRN Stock Holding History

Timber Hill’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,000
Closed -$357K – 328
2017
Q4 		$357K Sell
4,000
-9,400
-70% -$817K 0.02% 451
2017
Q3 		$1.25M Sell
13,400
-8,000
-37% -$707K 0.12% 156
2017
Q2 		$1.94M Buy
21,400
+4,600
+27% +$418K 0.07% 221
2017
Q1 		$1.48M Buy
16,800
+4,700
+39% +$418K 0.01% 845
2016
Q4 		$1M Sell
12,100
-6,600
-35% -$568K ﹤0.01% 1271
2016
Q3 		$1.73M Buy
18,700
+100
+0.5% +$9.42K 0.01% 859
2016
Q2 		$1.45M Buy
+18,600
New +$1.58M 0.01% 1056
2016
Q1 		– Sell
-2,000
Closed -$210K – 2088
2015
Q4 		$210K Sell
2,000
-18,900
-90% -$1.97M ﹤0.01% 2076
2015
Q3 		$2.2M Sell
20,900
-2,600
-11% -$347K 0.01% 959
2015
Q2 		$3.21M Sell
23,500
-29,200
-55% -$3.62M 0.01% 808
2015
Q1 		$6.57M Buy
52,700
+38,700
+276% +$4.1M 0.03% 464
2014
Q4 		$1.27M Buy
14,000
+8,300
+146% +$690K 0.01% 1291
2014
Q3 		$411K Sell
5,700
-16,200
-74% -$1.06M ﹤0.01% 2104
2014
Q2 		$1.36M Buy
21,900
+13,600
+164% +$822K 0.01% 1452
2014
Q1 		$566K Sell
8,300
-17,900
-68% -$1.32M ﹤0.01% 1975
2013
Q4 		$1.84M Sell
26,200
-16,100
-38% -$1.09M 0.01% 1431
2013
Q3 		$3.05M Sell
42,300
-31,400
-43% -$2.09M 0.01% 1160
2013
Q2 		$4.11M Buy
+73,700
New +$4.59M 0.02% 933

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Timber Hill's BMRN Position: Q4 2017 in Review

Timber Hill sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 7,606 shares — an estimated $661K sold.

Timber Hill first reported a position in BMRN in Q2 2013 and held it in 12 quarters. The position peaked at $1.39M in Q3 2016. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Timber Hill reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Timber Hill sold 7,606 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $661K.
  • Timber Hill first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Timber Hill's BioMarin Pharmaceuticals position peaked at $1.39M in Q3 2016.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Timber Hill's 13F filing for Q4 2017, filed 9 Feb 2018.